Advertisement
Device Sectors
Subscribe to Device Sectors
View Sample

FREE Email Newsletter

Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections

October 25, 2010 12:33 am | by Bio-Medicine.Org | News | Comments

VIENNA, Oct. 25 /- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa , a leading cause of hospital-acquired infections...

TearLab’s Goal Is to Make Sure There Isn’t a Dry Eye in the House

October 24, 2010 11:32 pm | by San Diego Business Journal | News | Comments

When James Owen first cast eyes on San Diego-based TearLab Corp.’s lab-on-a-chip approach to testing for eye disorders, he knew one major category of patients would be seeing improved results in their vision.

Experts unveil new CVD guidelines and position papers at Canadian Cardiovascular Congress 2010

October 24, 2010 10:31 pm | by EurekAlert | News | Comments

(Heart and Stroke Foundation of Canada) Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular...

Advertisement

Discovery of taste receptors in the lungs could help people with asthma breathe easier

October 24, 2010 11:31 am | by EurekAlert | News | Comments

(University of Maryland Medical Center) Taste receptors in the lungs? Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the...

NCPA Announces Kathleen Jaeger as CEO

October 24, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

ALEXANDRIA, Va., Oct. 24 /PRNewswire-USNewswire/ -- The National Community Pharmacists Association (NCPA) today announced the appointment of Kathleen Jaeger as Executive Vice President and CEO, heralding her as an ideal choice to build on the association's recent accomplishments and lead...

Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA

October 23, 2010 9:31 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 23 /- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America...

FDA Issues Complete Response Letter for Lorcaserin New Drug Application

October 23, 2010 12:31 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 23, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is...

Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing

October 22, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

BEIJING, Oct. 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS ) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the...

Advertisement

Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results

October 22, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

BELGRADE, Mont., Oct. 22 /- Bacterin International Holdings, Inc. (OTC Bulletin Board: BIHI ) ("Bacterin"), announced today that it has scheduled a conference call for Monday, November 15, 2010 at 10:00 a.m. (ET) to discuss the Company's financial results for its third quarter 2010, which...

AdvaMed 2010 Sets New Attendance Record: More than 1,700 Device and Diagnostics Leaders from Across the Country and Around the World Came to Washington, D.C.

October 22, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Oct. 22 /PRNewswire-USNewswire/ -- More than 1,700 medical device and diagnostics leaders from more than 360 companies – representing 24 countries and 33 states – attended the fourth annual industry gathering, AdvaMed 2010: The MedTech Conference this week in...

10 Tips for Breast Cancer Survivors

October 22, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Oct. 22 /- Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering weekly research-based tip sheets regarding breast cancer prevention, screening...

Studies: Pneumonia is misdiagnosed on patient readmissions

October 22, 2010 9:32 am | by EurekAlert | News | Comments

(Henry Ford Health System) Patients were misdiagnosed with pneumonia at an alarming rate when they were readmitted to the hospital shortly after a previous hospitalization for the same illness, according to two Henry Ford Hospital companion studies.

Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results

October 22, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, Oct. 22 /- Pharmaceutical company Pharmaxis (ASX: PXS) today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first...

Advertisement

Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent

October 22, 2010 8:31 am | by Bio-Medicine.Org | News | Comments

NATICK, Mass., Oct. 22 /- Boston Scientific Corporation (NYSE: BSX ) today announced that its WallFlex® Biliary RX Fully Covered Stent has received CE Mark approval for the treatment of benign biliary strictures.   "The WallFlex Biliary RX Fully Covered Stent has proved...

GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.

October 22, 2010 8:31 am | by Bio-Medicine.Org | News | Comments

CHALFONT ST GILES, UK and ALISO VIEJO, Calif., Oct. 22 /- GE Healthcare, a unit of General Electric Company (NYSE: GE ), and Clarient, Inc. (Nasdaq: CLRT ) announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the...

INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine

October 22, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

DENVER and BEVERLY, Mass., Oct. 22 /- INVO Bioscience, Inc. (OTC Bulltin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center (CECOFLES LTDA) will...

Social interaction can identify mental pathology

October 22, 2010 7:32 am | by Baylor College of Medicine | News | Comments

If your doctor thinks your blood pressure is too high, she can measure it with an instrument. If she thinks you are anemic, she can order a lab test. Psychiatrists seeking to identify mental disorders must depend on less precise measures – observations of behaviors and various...

Children's Hospital granted $3M to study rare blood disease

October 22, 2010 7:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Children’s Hospital Boston has received a $3.9 million grant from the National Institutes of Health to work on a treatment on a fatal genetic blood disease called Fanconi anemia.

Thoratec Schedules Third Quarter Conference Call, Webcast

October 22, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

PLEASANTON, Calif., Oct. 22 /- Thoratec Corporation (Nasdaq: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it will report its operating results for the third quarter and first nine months...

Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent

October 22, 2010 4:32 am | by Boston Scientific | News | Comments

Company's fully covered metal stent now approved for use in treating benign biliary strictures

New Label Changes for Commonly Prescribed HIV Drug Invirase

October 21, 2010 12:32 pm | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., Oct. 21 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that new safety information has been added to the label for the HIV antiviral drug Invirase (saquinavir), describing potentially life-threatening side effects on the heart when...

Federal Panel Grants Lanier Law Firm Motion for Hearing on National Coordination of DePuy Hip Implant Lawsuits

October 21, 2010 11:34 am | by Bio-Medicine.Org | News | Comments

HOUSTON, Oct. 21 /- A panel of seven federal judges has granted The Lanier Law Firm 's motion for a hearing to determine the national coordination of all DePuy hip device cases in In re: DePuy Orthopaedics Inc. ASR Hip Implant Products Liability Litigation ( MDL 2197 ) . The United States...

AACR Congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award

October 21, 2010 11:32 am | by AACR | News | Comments

PHILADELPHIA — The American Association for Cancer Research expresses its congratulations to and appreciation of William S. Dalton, M.D., Ph.D., who will receive the 2010 Leadership in Personalized Medicine Award from the Personalized Medicine Coalition (PMC). Dalton, who has been a...

Rhythmlink International Announces Change in Engineering Management

October 21, 2010 11:32 am | by Bio-Medicine.Org | News | Comments

COLUMBIA, S.C., Oct. 21 /- Engineering executive Harold Kaefer has been named Rhythmlink's new director of engineering. With over 20 years of experience within the medical device, diagnostic and laser industries, Mr. Kaefer will provide project and engineering management to Rhythmlink's...

CareFusion Will Host an Earnings Conference Call on Nov. 2 to Discuss the Results for the First Quarter Fiscal 2011

October 21, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 21 /- CareFusion (NYSE: CFN ), a leading, global medical device company, today announced plans to release first quarter fiscal 2011 results on Tuesday, Nov. 2 before the start of trading on the New York Stock Exchange. (Logo:  ...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading